LIV by WellNow Review
Best for: Patients in IL, IN, MI, NY, or PA wanting flat all-inclusive compounded semaglutide
LIV by WellNow is the telehealth weight-management arm of WellNow Urgent Care, offering compounded semaglutide for weight loss. The flat $279 per month price covers medication, injection supplies, and unlimited virtual visits with board-certified online providers, plus same-day approval and monthly home delivery. Eligibility requires age 18+ and a BMI of 30+, or 27+ with a weight-related condition. Compounded semaglutide is not FDA-approved. Service is limited to Illinois, Indiana, Michigan, New York, and Pennsylvania, and insurance is not accepted.
High confidence · Last verified 2026-06-04 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
LIV by WellNow is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
LIV by WellNow prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| All-inclusive monthly | compounded | $279 |
✓ Pros
- •Flat $279/month covers medication, supplies, and unlimited virtual visits
- •Backed by established WellNow Urgent Care brand
- •Board-certified online medical providers
- •Same-day approval and monthly home delivery
- •Transparent all-inclusive pricing with no hidden fees
✗ Cons
- •Compounded semaglutide is not FDA-approved or evaluated
- •Only available in five states (IL, IN, MI, NY, PA)
- •No tirzepatide option offered
- •Insurance not accepted for compounded semaglutide
Ready to start with LIV by WellNow?
Starting at $279/month. See current pricing and start your free consultation.
Sources & methodology
Our LIV by WellNow review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to LIV by WellNow
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with LIV by WellNow?
Starting at $279/month. See current pricing and start your free consultation.